Uroguanylin, a member of the guanylin peptide family, acts on guanylyl cyclase C (GC-C) to regulate intestinal and renal fluid and electrolyte transport through the second messenger, cGMP. Using an antiserum raised against synthetic rat uroguanylin, we established an RIA and identified three endogenous molecular forms in the intestine and kidney: a 15-amino acid uroguanylin, an 18-amino acid uroguanylin that is a monobasic processing product, and a 9.4-kDa prouroguanylin. Prouroguanylin is the major molecular form in these two tissues, whereas only 15-amino-acid uroguanylin is present in the urine. Rat uroguanylin is most abundant in the proximal small intestine, its content decreasing toward the colon. Uroguanylin is present immunohistochemically in the endocrine cells in the intestine and stomach, B cells in the pancreatic islets, and tubular epithelial cells in the kidney. Uroguanylin has a widespread tissue distribution and is located in cells that function in an endocrine, paracrine, and/or luminocrine (luminal secretion) fashion. Uroguanylin may have physiological functions other than the regulation of fluid and electrolyte transport in the intestine and kidney. (Endocrinology 139: [5247][5248][5249][5250][5251][5252][5253][5254] 1998) 
G UANYLIN and uroguanylin are novel peptide regulators of intestinal, and possibly renal, salt and water transport (1) (2) (3) (4) (5) (6) . These two peptides consist of 15-16 amino acids and have a conserved backbone of two disulfide bridges that are essential for their biological activities. They bind to and activate guanylyl cyclase C (GC-C), an apical membrane receptor that has a guanylyl cyclase catalytic domain within the receptor molecule. Included in this family are guanylyl cyclase A (GC-A) and guanylyl cyclase B (GC-B), which serve as receptors for the natriuretic peptide family of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) (reviewed in Ref. 7) . The increase in cGMP induced by GC-C activates type II cGMP-dependent protein kinase (8) , then opens the cystic fibrosis transmembrane conductance regulator (CFTR) Cl Ϫ channel with subsequent secretion of Cl Ϫ (9 -11). Heat-stable enterotoxins elaborated by pathogenic bacteria have close structural similarities to guanylin and uroguanylin and use this molecular mimicry to act on GC-C, causing life-threatening secretory diarrhea (12) (13) (14) .
Human uroguanylin has been isolated from the urine and opossum and rat uroguanylin from the urine and small intestine (5, 6, 15, 16) . Uroguanylin circulates in the blood (17) (18) (19) . Iv administration to the mouse has a natriuretic effect (20) . Together with the presence of the GC-C transcript in human and rat kidney (21) , these findings suggest that uroguanylin serves as an endocrine factor; an "intestinal natriuretic peptide" that carries information from the intestine to the kidney. To better understand its physiological functions and pathophysiological significance in water and electrolyte homeostasis, we generated an antiserum specific for rat uroguanylin then developed an RIA, after which we isolated endogenous molecular forms of uroguanylin and determined their amino acid sequences. Three uroguanylin molecules, a 15-amino acid uroguanylin (uroguanylin-15), an 18-amino acid uroguanylin (uroguanylin-18), and a 9.4-kDa prouroguanylin were identified. The antiserum recognized the first two small peptides equally on a molar basis, but not prouroguanylin because its tertiary structure probably interfered with the binding of the antibody to this large molecule. To determine the tissue content and ratios of the three molecular forms, we produced uroguanylin-18 from prouroguanylin by trypsin digestion before doing the RIA. We also investigated immunohistochemically the cellular origin of uroguanylin with three independent antisera, one for uroguanylin-15 and two for N-terminal regions of prouroguanylin.
thesized by solid phase techniques. Two disulfide bonds at positions 4 and 12, and 7 and 15 were successively linked by a two-step selectiveforming reaction (22) . The validity of the synthesis was confirmed by amino acid analysis, sequencing, and mass spectrometric analysis.
Preparation of antisera
To generate an antiuroguanylin antiserum, synthetic rat uroguanylin-15 (2 mg) was conjugated with bovine thyroglobulin (15 mg) in 200 l of a 5% glutaraldehyde solution. The reaction mixture was dialyzed four times against 3 liters of 0.9% sodium chloride. Amino acid analysis of the conjugate showed that one thyroglobulin molecule was coupled with an average 280 uroguanylin molecules. The antigenic conjugate solution (1.5-3 ml) was emulsified with an equal volume of Freund's complete adjuvant and administered to New Zealand white rabbits. Booster injections were given every 2 weeks, and the animals bled 7 days after each injection. Two antisera (6910 and 6912) raised against Nterminal regions of rat prouroguanylin are described elsewhere (23) .
RIA procedure
Synthetic rat Tyr 0 -uroguanylin-15 was radioiodinated by the lactoperoxidase method. The 125 I-labeled peptide was purified on a TSK ODS SIL 120A column (Tosoh Co. Ltd., Tokyo, Japan) by reverse-phase high performance liquid chromatography (RP-HPLC). The RIA incubation buffer was 50 mm sodium phosphate (pH 7.4) that contained 0.25% BSA treated with N-ethylmaleimide, 80 mm NaCl, 25 mm EDTA⅐2 Na, 0.05% NaN 3 , and 0.1% Triton X-100. A diluted sample or a standard peptide solution (100 l) was incubated for 24 h with 100 l of the antiserum diluent (final dilution 1/10,000). The tracer solution (16,000 cpm in 100 l) was added, and the mixture again incubated for 24 h. The bound and free ligands were separated in 23% polyethyleneglycol solution (500 l). All the procedures were done at 4 C. The cross-reactivity of the antiserum was examined using rat guanylin and 94-amino acid rat proguanylin that had been isolated from the intestinal mucosa (24) , and human uroguanylin (Fig. 1) .
Isolation of uroguanylin-15 and uroguanylin-18
The intestinal mucosa (71.4 g wet wt), from the duodenum to the ileum, was collected from 27 male Sprague Dawley rats. The tissue was heated at 95-100 C for 10 min in a 10-fold volume of water to inactivate intrinsic proteases. After cooling to 4 C, CH 3 COOH and HCl were added to the respective final concentrations of 1 m and 20 mm, after which the tissue was homogenized in a Polytron for 10 min. The homogenate was centrifuged at 11,500 ϫ g for 30 min. The supernatant was applied to an octadecylsilica column (90 ml, Chemcosorb LC-SORB SPW-C-ODS, Chemco Ltd., Osaka, Japan), washed with 0.5 m CH 3 COOH and 0.1% TFA, then eluted with a 60% CH 3 CN solution containing 0.1% TFA. The eluate was loaded on an SP-Sephadex C-25 column (H ϩ -form, 1.8 ϫ 4 cm, Pharmacia Biotech, Piscataway, NJ), preequilibrated with 1 m CH 3 COOH. The column was washed with 1 m CH 3 COOH (SP-I fraction) then treated successively with 2 m pyridine (SP-II fraction) and 2 m pyridine acetate (pH 5.0) (SP-III fraction). The SP-II fraction that contained immunoreactive (ir-) uroguanylin was evaporated repeatedly to remove pyridine, and then it was lyophilized. The dried SP-II material was subjected to gel filtration on a Sephadex G-75 fine column (Pharmacia Biotech) with 1 m CH 3 COOH as the elution solvent (Fig. 2) . Fractions 58 -63 that contained ir-uroguanylin were pooled and lyophilized. The residue was dissolved in 0.1 m sodium phosphate buffer (pH 7.4) containing 0.05% Triton X-100 then subjected to immunoaffinity chromatography on an antirat uroguanylin IgG-bound Affi-Gel 10 column (gel volume: 4 ml) as described below. The adsorbed peptides were eluted with a solution of 1 m CH 3 COOH containing 10% CH 3 CN and 0.002% Triton X-100. The eluate was subjected to RP-HPLC on a TSK-ODS-SIL 120A column under the conditions described in the legend to Fig. 3A . All fractions were analyzed by RIA for uroguanylin immunoreactivity. The two uroguanylin-immunoreactive peptides were purified by RP-HPLC on a Bondasphere C-18 300 Å column (Waters, Milford, MA) (Fig. 3 , B and C). They were subjected to a gas-phase protein sequencer (Model 476A, PE Applied Biosystems, Foster City, CA) linked on-line to a PTH analyzer (Model 120A, PE Applied Biosystems). Amino acid sequences thus determined are shown in Fig. 4 .
Immunoaffinity chromatography
The IgG fraction was purified from 5 ml of the antiserum for rat uroguanylin-15 using Protein A-Sepharose CL-4B (Pharmacia Biotech). IgG was coupled to 5 ml of Affi-Gel 10 resin (Bio-Rad Laboratories, Inc., Richmond, CA). More than 95% of the IgG was coupled to the resin. The capacity of the immunoaffinity resin for binding rat uroguanylin-15 was 0.3 g/1 ml gel.
Quantification and chromatographic characterization of iruroguanylin in tissues and urine
The tissues (ϳ1 g wet wt each) listed in Table 1 were resected immediately after decapitation of five 8-week-old male Sprague Dawley rats that had fasted overnight. The jejunum was resected 10 -20 cm from the pyloric ring, the ileum 20 -30 cm above the terminal ileum, and the colon 5-15 cm below the terminal ileum. Twenty-four hour urine samples were obtained from the same five rats. All the rats were kept in an air-conditioned room and given standard laboratory chow and water ad libitum.
The tissues were heated and homogenized as described above, after which the homogenates were centrifuged. The supernatants were applied to Sep-Pak C-18 cartridges (Waters) then the peptides were eluted with 60% CH 3 CN solution containing 0.1% TFA. Portions of each eluate, equivalent to 200 mg wet wt, were lyophilized then digested with 20 g of trypsin (Sigma Chemical Co., St. Louis, MO) for 8 h at 37 C in 100 l of 0.1 m Tris-HCl buffer (pH 8.0). The reaction was terminated by the addition of 40 g of soy trypsin inhibitor (Sigma Chemical Co.) in 300 l of the RIA buffer. The resulting samples were subjected to the RIA for uroguanylin. Other portions of the Sep-Pak eluate were subjected to RP-HPLC (Fig. 5, A and B) . Five milliliters of rat urine was applied to a Sep-Pak C-18 cartridge, then the eluate was separated by RP-HPLC (Fig. 5C ). One-half of each RP-HPLC fraction was quantified by the RIA without trypsin digestion, and the other half by the RIA after trypsin digestion. Authentic rat uroguanylin-15 and -18 were chromatographed with the same HPLC system. The ir-fractions eluting at about 31 min (Fig. 5A ) were subjected to gel permeation chromatography on a TSKgel G2000 SW column (Fig. 5D ) and all fractions were analyzed by RIA after trypsin digestion. The recoveries of rat uroguanylin during extraction were determined by adding rat uroguanylin-15 ( 
Immunohistochemistry
The gastrointestinal tract, pancreas, and kidney were obtained from the five rats used above. The tissues were fixed with 3.7% formaldehyde in 10 mm PBS (pH 7.2), dehydrated in a graded ethanol series, then embedded in paraffin. Sections cut 3 m thick were deparaffinized in xylene, then rehydrated in a graded ethanol series, after which they were treated with 0.3% hydrogen peroxide for 30 min to inactivate endogenous peroxidases. Nonspecific bindings were blocked with normal goat serum when assessing uroguanylin and chromogranin A immunoreactivities and with normal horse serum when assessing serotonin immunoreactivity. The preparations were incubated overnight at 4 C in 10 mm PBS with antiuroguanylin-15 antiserum used at the final dilution of 1/2,000 or N-terminally directed antisera for rat prouroguanylin used at the final dilution of 1/2,000. In addition, serial sections of the stomach were incubated overnight at 4 C with anti-chromogranin A antiserum (Dako Corp. A/S, Glostrup, Denmark) diluted 1/100 in 10 mm PBS and those of the jejunum with anti-serotonin antiserum (Dako Corp. A/S) diluted 1/5 in 10 mm PBS. Goat-biotinylated antirabbit IgG (Vectastain, Vector Laboratories, Inc., Burlingame, CA) was used as the second antibody for uroguanylin, prouroguanylin and chromogranin A staining, and horse-biotinylated antimouse IgG (Vectastain) for serotonin staining. These specimens were allowed to react for 60 min with peroxidase-conjugated streptavidin (Gibco BRL, Gaithersburg, MD) diluted 1/200 in 10 mm PBS. They then were stained for 3 min at room temperature with 20 mg of 3, 3Ј-diaminobenzidine tetrahydrochloride (Sigma Chemical Co.) and 0.006% hydrogen peroxide in 50 mm Tris buffer solution (pH 7.2), then counterstained with methyl green. In the sequential double staining for uroguanylin vs. insulin in the pancreas, uroguanylin first was stained by the streptavidin-peroxidase method, after which the specimens were washed with 0.1 m glycine-HCl buffer (pH 2.2) and stained with antiinsulin antiserum by the streptavidinalkaline phosphatase method using a Labelled Streptavidin Biotin kit (Dako Corp. A/S) and an AP Substrate Kit III (Vectastain). Control studies were done with normal rabbit serum or anti-uroguanylin antiserum that had been absorbed with 10 g of rat uroguanylin-15.
Results

RIA for rat uroguanylin
We confirmed the structure of our synthetic rat uroguanylin-15 by showing that it increased cGMP production in cultured T84 cells dose dependently between 10 Ϫ9 and 10 Ϫ6 m (25). We raised an antiserum against this bioactive rat uroguanylin-15. Half-maximum inhibition by rat uroguanylin-15 on the standard RIA curve was 32 fmol/tube, and the peptide was detectable at the low level of 8 fmol/tube (Fig.  1) . The antiserum had 100% cross-reactivity with isolated uroguanylin-18, but no cross-reactivity with rat guanylin, rat proguanylin, or human uroguanylin. The dilution curves for the extracts of rat jejunum and urine paralleled the standard curve, and the respective intra and interassay coefficients of variation were 4.1% and 3.8% at 50% binding. The recoveries of the "cold" and radiolabeled uroguanylin-15 added to the tissue homogenates in the extraction done with a Sep-Pak C-18 cartridge respectively were 91.8 Ϯ 0.4% (sem) and 88.6 Ϯ 0.7% (sem).
Isolation and sequence determination of uroguanylin-15 and uroguanylin-18
Two uroguanylin molecules were purified from small intestinal mucosa as single peptide peaks using Sephadex G-75 gel filtration (Fig. 2 ) and immunoaffinity chromatography, followed by two steps of RP-HPLC (Fig. 3) . The elution position of the peptide in fractions 17-19 in Fig. 3A was identical to that of authentic rat uroguanylin-15. The yield of this peptide was 23 pmol and that of the other ir-peptide 22 pmol on the basis of immunoreactivity. Amino acid sequence analysis verified that the former peptide was uroguanylin-15 and the latter uroguanylin-18 with three N-terminalextended amino acids (Fig. 4) .
Identification of ir-uroguanylin molecules in tissues and urine
In our study of gel filtration without trypsin digestion, we detected uroguanylin-15 and -18 in rat intestine, but not their precursor form. Because rat guanylin has a 10.4-kDa precursor form as a major molecule in the intestine (24) and on the assumption that rat uroguanylin-18 must be a monobasic processing product of its precursor, we analyzed the uroguanylin molecules in the jejunum, kidney, and urine using a combination of RP-HPLC and trypsin digestion. The kidney sample was loaded on a medium-sized HPLC column because its uroguanylin content was much lower than that in the jejunum. Two ir-peptides, uroguanylin-15 (arrow 1) and uroguanylin-18 (arrow 2), were detected on the chromatograms of the jejunum and kidney when the HPLC fraction samples were not trypsinized (Fig. 5, A and B, closed circles) . We detected the presence of rat uroguanylin precursor by digesting the HPLC fraction samples with trypsin then analyzing the products using the RIA (Fig. 5, A and B, open  circles) . This revealed a new immunoreactive peak (arrow 3 in Fig. 5 ), eluting later than uroguanylin-18. To further characterize this peptide of arrow 3, it was subjected to gel permeation chromatography. Samples of the fractions then were trypsinized and subjected to the RIA (Fig. 5D) . Uroguanylin immunoreactivity was detected at the position corresponding to M r 9.4K. This 9.4-kDa precursor produced uroguanylin-18 after trypsin digestion (data not shown). The molar ratios of uroguanylin-15, uroguanylin-18, and the precursor were 1:2:5 in the jejunum and 5:1:7 in the kidney. Only uroguanylin-15 was detected in the urine (Fig. 5C ).
Tissue content and urine concentration of ir-uroguanylin
Uroguanylin is present in the gastrointestinal tract from the stomach to the colon, as well as in the kidney, the highest value being in the jejunum (Table 1) . Uroguanylin was found immunohistochemically in the pancreas (as described below), but its content in this tissue was below the detectable level (0.05 pmol/g wet wt). No uroguanylin was detected in the other tissues examined including the esophagus, heart, liver, lung, spleen, cerebrum, and cerebellum. The urine concentration of uroguanylin in 5 normal rats was 345 Ϯ 30 fmol/ml (mean Ϯ sem).
Immunohistochemistry of uroguanylin-positive cells
We used three independent antisera, one for uroguanylin-15 and two for N-terminal regions of prouroguanylin, in immunohistochemistry. Because the two antiprouroguanylin antisera display indistinguishable staining patterns (23) , only results obtained with 6912 are shown in the figures. Uroguanylin-immunoreactive cells are moderately abundant in the duodenum (Fig. 6A) , most abundant in the jejunum (Fig. 6B) , infrequent in the ileum (Fig. 6C ), and vary rare in the colon. These cells are predominant in the midvilli of the small intestine along the crypt-villus axis (Fig. 6, A and  B) . Uroguanylin-immunoreactive cells are round, basketshaped, or tall flask-shaped cells with a dense accumulation of uroguanylin in the luminal cytoplasm and a long, thin basal process immunoreactive for uroguanylin (Fig. 6D) . Most uroguanylin-positive cells in the intestine are prouroguanylin-positive and also reacted with serotonin antibody in serially cut sections (Fig. 6, E-G) . In the stomach, uroguanylin-immunoreactive cells are present in the epithelium of the basal half of the oxyntic mucosa (Fig. 6H ), but not in the cardia or antrum. These cells also reacted with chromogranin A (Fig. 6I) and prouroguanylin (data not shown) . None of the uroguanylin-immunoreactive cells showed somatostatin or gastrin immunoreactivity (data not shown). Uroguanylin and prouroguanylin immunoreactivities are present in the pancreatic islet (Fig. 6, J and K) , where colocalization of uroguanylin and insulin occurred in a doubleimmunostaining section (Fig. 6L) . In the kidney, uroguanylin-15 is present in the distal tubules, but not in the proximal tubules or glomeruli (Fig. 6 m) . These cells showed no immunoreactivity for prouroguanylin (Fig. 6N) . No uroguanylin immunoreactivity was detected in the tissues studied when normal rabbit serum or antiserum absorbed with excessive synthetic uroguanylin-15 was used (Fig. 6O) .
Discussion
We now have isolated uroguanylin-15 and -18 from the intestinal mucosa using an RIA specific for rat uroguanylin and have confirmed their identity by amino acid sequence determination. Taken together with the cGMP production activity of uroguanylin-15 and its sequence homology with rat and human guanylin (Fig. 4) , rat uroguanylin-15 must be the final processing product that activates GC-C. All mature forms of uroguanylin and guanylin in humans and the rat are produced by cleavage of the peptide bond between the Ϫ4 and Ϫ3 positions from the first cysteine residue in these molecules (Fig. 4) . This processing produces two intramolecular disulfide bonds indispensable for bioactivity at the same position in these peptides. However, there is no common amino acid sequence at the position where this processing occurs in the uroguanylin and guanylin precursors (Fig. 4) . Crystallization of the precursors and analysis by x-ray diffraction should provide direct structural information about their conformations as well as clues to the contribution of the substrate structure to this processing.
Rat uroguanylin-18 had been isolated from the duodenum by the use of a cGMP functional assay with T84 cells (16) . The peptide is considered a monobasic processing product of its precursor because the amino acid sequence in the vicinity where cleavage occurs is consistent with the following consensus sequences that govern monobasic cleavage (26, 27) : an arginine, a target for monobasic cleavage, is located next to the N-terminus of uroguanylin-18 within the prouroguanylin sequence (Fig. 4) ; a basic amino acid is always present at the Ϫ3, Ϫ5, or Ϫ7 position (the 3rd, 5th, or 7th amino acid preceding the monobasic cleavage site), in this case Lys at the Ϫ3 position; short-side chain amino acids occur at the Ϫ2 and ϩ1 positions, in this case Ala at the Ϫ2 and Thr at the ϩ1; cysteine and aromatic amino acids (Trp, Tyr, and Phe) are never present at the Ϫ1 position, in this case Leu at the Ϫ1; and an aliphatic amino acid, Ile in this case, is present at the ϩ2 position. We identified a 9.4-kDa uroguanylin precursor in the intestine and kidney. Hamra et al. (28) have purified prouroguanylin from opossum intestine by using pretreatment of prouroguanylin with chymotrypsin to elicit cGMP responses in T84 cells. Although we did not determine the N-terminal sequence of the rat uroguanylin precursor, its molecular size is consistent with that of the 85-amino acid rat prouroguanylin (M r ϭ 9405.3) that is generated by cleavage of the putative 21-residue signal peptide from preprouroguanylin. Moreover, the precursor produced uroguanylin-18 by trypsin digestion, indicative that it is prouroguanylin. The antiserum recognized uroguanylin-15 and -18 on a molar basis, but not prouroguanylin. This could be due to elements of tertiary structure that interfere with the binding of the antibody to this large molecule. We therefore determined the tissue content and ratio of the endogenous molecular forms of uroguanylin after trypsin digestion. Prouroguanylin accounted for about half the ir-uroguanylin molecules in the intestine and kidney, as is the case for rat proguanylin in the intestine (24) .
Uroguanylin is present not only in the intestine but also in the stomach, kidney, and pancreas. Uroguanylin is most abundant in the proximal small intestine, its content and the number of uroguanylin-positive cells decreasing toward the colon. These findings agree with its messenger RNA (mRNA) distribution and abundance (16, 25, 29) . A previous report (23) and this study indicate that uroguanylin-containing cells in intestinal epithelia are enterochromaffin (EC) cells. The EC cell, the most abundant type of enteroendocrine cell, is widely distributed in the intestine. When stimulated, the EC cell releases serotonin and substance P both apically (into the lumen) and basolaterally (into circulation) (30) . Uroguanylin also is released from the intestine bidirectionally (unpublished data) and is thought to function in a luminocrine (luminal secretion), endocrine, and/or paracrine fashion. Identification of the EC cell as the site of uroguanylin biosynthesis suggests a feasible mechanism for delivering uroguanylin to luminally oriented GC-C as well as to remote tissues such as the kidney via the circulation.
Uroguanylin-containing cells in the gastric fundus appear to be endocrine cells on the basis of their morphological features and colocalization with chromogranin A. These uroguanylin-containing cells had no immunoreactivity for gastrin or somatostatin. The expression of GC-C and a truncated, GC-C-like mRNA that has a 159-nucleotide deletion has been reported in the mucosa of both rat stomach and intestine (31) . Further identification of the cellular source of uroguanylin in the stomach should help clarify the cGMPmediated-regulation of gastric ion transport.
Uroguanylin-15 is present immunohistochemically in the renal distal tubules whose principal function is to regulate the reabsorption of sodium and chloride from the glomerular filtrate. The distal tubules did not react with two antiprouroguanylin antisera. This could result from receptormediated uptake of bioactive uroguanylin-15 from the glomerular filtrate. We reported that the 24 h urinary excretion of uroguanylin of persons on a high-salt diet (10 g/day) was significantly higher than that of persons on a low-salt diet (7 g/day) (21) . There was a significant positive correlation between the urinary excretions of ir-uroguanylin and Na ϩ , Cl Ϫ , K ϩ , or cGMP in these persons, but not between the plasma levels of ir-ANP and ir-BNP and the urinary excretions of Na ϩ , Cl Ϫ , and K ϩ . Iv injection of 75 ng of opossum uroguanylin, but not guanylin, to mice induced 3-fold urinary sodium excretion and 2-fold diuresis as compared with the control vehicle (20) . Uroguanylin therefore is a prime candidate for a substance that could link the intestine and kidney in an endocrine pathway that regulates renal salt metabolism.
Uroguanylin was found in B-cells of the pancreatic islets by double immunostaining with antiinsulin antiserum. We also detected uroguanylin mRNA in rat pancreatic islets by using the RT-PCR (unpublished data). The peptides produced in the "gastro-entero-pancreatic (GEP) endocrine system" function to control or modulate all the processes linked to the digestion and absorption of nutrients and water (32) . Uroguanylin may be a constituent of the GEP endocrine system because of its cellular source and biological activity. Alternatively, uroguanylin in the pancreas may be merely a vestige of the evolutional process.
Our findings have furnished new insights into the potential roles of uroguanylin via intracellular cGMP in various organs and tissues. Further investigations of the uroguanylin contents of the tissues, plasma, urine, and intestinal perfusate under various physiological and pathophysiological conditions should provide information on what mechanisms govern the biosynthesis and secretion of this peptide.
